210 related articles for article (PubMed ID: 31582819)
1. Fine tuning of the DNAM-1/TIGIT/ligand axis in mucosal T cells and its dysregulation in pediatric inflammatory bowel diseases (IBD).
Battella S; Oliva S; Franchitti L; La Scaleia R; Soriani A; Isoldi S; Capuano C; Pighi C; Morrone S; Galandrini R; Santoni A; Palmieri G
Mucosal Immunol; 2019 Nov; 12(6):1358-1369. PubMed ID: 31582819
[TBL] [Abstract][Full Text] [Related]
2. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
3. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
4. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
[TBL] [Abstract][Full Text] [Related]
5. Critical Role of CD6highCD4+ T Cells in Driving Th1/Th17 Cell Immune Responses and Mucosal Inflammation in IBD.
Ma C; Wu W; Lin R; Ge Y; Zhang C; Sun S; Cong Y; Li X; Liu Z
J Crohns Colitis; 2019 Mar; 13(4):510-524. PubMed ID: 30395204
[TBL] [Abstract][Full Text] [Related]
6. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction.
Ardolino M; Zingoni A; Cerboni C; Cecere F; Soriani A; Iannitto ML; Santoni A
Blood; 2011 May; 117(18):4778-86. PubMed ID: 21406724
[TBL] [Abstract][Full Text] [Related]
7. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
[TBL] [Abstract][Full Text] [Related]
8. Frequencies of circulating regulatory TIGIT
Joosse ME; Menckeberg CL; de Ruiter LF; Raatgeep HRC; van Berkel LA; Simons-Oosterhuis Y; Tindemans I; Muskens AFM; Hendriks RW; Hoogenboezem RM; Cupedo T; de Ridder L; Escher JC; Veenbergen S; Samsom JN
Mucosal Immunol; 2019 Jan; 12(1):154-163. PubMed ID: 30127383
[TBL] [Abstract][Full Text] [Related]
9. DNAM-1 regulates Foxp3 expression in regulatory T cells by interfering with TIGIT under inflammatory conditions.
Sato K; Yamashita-Kanemaru Y; Abe F; Murata R; Nakamura-Shinya Y; Kanemaru K; Muratani M; Veillette A; Goto M; Ito M; Shibuya A; Shibuya K
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34011606
[TBL] [Abstract][Full Text] [Related]
10. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
11. Expression of CCR6 and CXCR6 by Gut-Derived CD4
Godefroy E; Alameddine J; Montassier E; Mathé J; Desfrançois-Noël J; Marec N; Bossard C; Jarry A; Bridonneau C; Le Roy A; Sarrabayrouse G; Kerdreux E; Bourreille A; Sokol H; Jotereau F; Altare F
Gastroenterology; 2018 Oct; 155(4):1205-1217. PubMed ID: 29981781
[TBL] [Abstract][Full Text] [Related]
12. CD155 and Its Receptors as Targets for Cancer Therapy.
Paolini R; Molfetta R
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629138
[TBL] [Abstract][Full Text] [Related]
13. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.
Stanietsky N; Rovis TL; Glasner A; Seidel E; Tsukerman P; Yamin R; Enk J; Jonjic S; Mandelboim O
Eur J Immunol; 2013 Aug; 43(8):2138-50. PubMed ID: 23677581
[TBL] [Abstract][Full Text] [Related]
14. Characteristic of TIGIT and DNAM-1 Expression on Foxp3+
Jin Z; Ye W; Lan T; Zhao Y; Liu X; Chen J; Lai J; Chen S; Zhong X; Wu X
Biomed Res Int; 2020; 2020():4612952. PubMed ID: 32802845
[TBL] [Abstract][Full Text] [Related]
15. NKG2D/Ligand dysregulation and functional alteration of innate immunity cell populations in pediatric IBD.
La Scaleia R; Stoppacciaro A; Oliva S; Morrone S; Di Nardo G; Santoni A; Cucchiara S; Palmieri G
Inflamm Bowel Dis; 2012 Oct; 18(10):1910-22. PubMed ID: 22294522
[TBL] [Abstract][Full Text] [Related]
16. Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease.
Sato T; Kanai T; Watanabe M; Sakuraba A; Okamoto S; Nakai T; Okazawa A; Inoue N; Totsuka T; Yamazaki M; Kroczek RA; Fukushima T; Ishii H; Hibi T
Gastroenterology; 2004 Mar; 126(3):829-39. PubMed ID: 14988837
[TBL] [Abstract][Full Text] [Related]
17. Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.
Hattori N; Kawaguchi Y; Sasaki Y; Shimada S; Murai S; Abe M; Baba Y; Watanuki M; Fujiwara S; Arai N; Kabasawa N; Tsukamoto H; Uto Y; Yanagisawa K; Saito B; Harada H; Nakamaki T
Biol Blood Marrow Transplant; 2019 May; 25(5):861-867. PubMed ID: 30639819
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2/caspase 3 mucosal imbalance favors T cell resistance to apoptosis in dogs with inflammatory bowel disease.
Jergens A; Young J; Moore D; Wang C; Hostetter J; Augustine L; Allenspach K; Schmitz S; Mosher C
Vet Immunol Immunopathol; 2014 Apr; 158(3-4):167-74. PubMed ID: 24495616
[TBL] [Abstract][Full Text] [Related]
19. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
Gorvel L; Olive D
F1000Res; 2020; 9():. PubMed ID: 32489646
[TBL] [Abstract][Full Text] [Related]
20. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
